Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

BACKGROUND: The role and the durability of the immunogenicity of the third dose of vaccine against COVID-19 variants of concern in cancer patients have to be elucidated. PATIENTS AND METHODS: We have prospectively evaluated the immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 messenger RN...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Serra, F., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353611/
https://www.ncbi.nlm.nih.gov/pubmed/36029652
http://dx.doi.org/10.1016/j.esmoop.2022.100574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353611/
https://www.ncbi.nlm.nih.gov/pubmed/36029652
http://dx.doi.org/10.1016/j.esmoop.2022.100574

Ejemplares similares